Background Nonalcoholic fatty liver disease (NAFLD) is one of the critical public health problems in China. The full spectrum of the disease ranges from simple steatosis and nonalcoholic steatohepatitis (NASH) to cirrhosis and hepatocellular carcinoma(HCC). The infiltration of inflammatory cells characterizes NASH. This characteristic contributes to the progression of hepatitis, fibrosis, cirrhosis, and HCC. Therefore, distinguishing NASH from NAFLD is crucial. Objective and Methods Ninety-five patients with NAFLD, 44 with NASH, and 51 with non-NASH were included in the study to develop a new scoring system for differentiating NASH from NAFLD. Data on clinical and biological characteristics, as well as blood information, were obtained. Cytokeratin-18 (CK-18) fragments levels were measured using an enzyme-linked immunosorbant assay. Results Several indexes show significant differences between the two groups, which include body mass index (BMI), waist-on-hip ratio (WHR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GT), platelets, uric acid (UA), hs-C-reactive protein (hs-CRP), triglycerides (TG), albumin (ALB), and CK-18 fragments (all P < 0.05). The CK-18 fragment levels showed a significant positive correlation with steatosis severity, ballooning, lobular inflammation, and fibrosis stage (all P < 0.05). Therefore, a new model that combines ALT, platelets, CK-18 fragments, and TG was established by logistic regression among NAFLD patients. The AUROC curve in predicting NASH was 0.920 (95% CI: 0.866 - 0.974, cutoff value = 0.361, sensitivity = 89%, specificity = 86%, positive predictive value = 89%, negative predictive value = 89%). Conclusion The novel scoring system may be considered as a useful model in predicting the presence of NASH in NAFLD patients.
References
[1]
de Alwis NM, Day CP (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48: S104-S112. doi:10.1016/S0168-8278(08)60259-7. PubMed: 18304679.
[2]
Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF et al. (2011) Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 106: 460-468. doi:10.1038/ajg.2010.488. PubMed: 21206486.
[3]
Fan JG, Jia JD, Li YM, Wang BY, Lu LG et al. (2011) Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis 12: 38-44. doi:10.1111/j.1751-2980.2010.00476.x. PubMed: 21276207.
[4]
Fan JG, Farrell GC (2009) Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50: 204-210. doi:10.1016/S0168-8278(09)60554-7. PubMed: 19014878.
[5]
Afdhal NH (2012) Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA 308: 608-616. doi:10.1001/jama.2012.8402. PubMed: 22760235.
[6]
Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M et al. (2010) Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo) 56: 271-278. doi:10.3177/jnsv.56.271. PubMed: 21228496.
[7]
Das K, Kar P (2005) Non-alcoholic steatohepatitis. J Assoc Physicians India 53: 195-199. PubMed: 15926603.
[8]
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219. doi:10.1053/jhep.2003.50193. PubMed: 12717402.
[9]
Vos MB, Barve S, Joshi-Barve S, Carew JD, Whitington PF et al. (2008) Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 47: 481-485. doi:10.1097/MPG.0b013e31817e2bfb. PubMed: 18852641.
[10]
Zelber-Sagi S, Ratziu V, Zvibel I, Goldiner I, Blendis L et al. (2012) The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol 24: 262-269. doi:10.1097/MEG.0b013e32834f15dd. PubMed: 22246329.
[11]
McCullough AJ (2004) The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8: 521-533. doi:10.1016/j.cld.2004.04.004. PubMed: 15331061.
[12]
Neuschwander-Tetri BA (2005) Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330: 326-335. doi:10.1097/00000441-200512000-00011. PubMed: 16355018.
[13]
Castera L, Forns X, Alberti A (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847. doi:10.1016/j.jhep.2008.02.008. PubMed: 18334275.
[14]
Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL et al. (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51: 454-462. doi:10.1002/hep.23312. PubMed: 20101745.
[15]
Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Beaton M et al. (2012) Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 56: 564-570. doi:10.1016/j.jhep.2011.10.007. PubMed: 22027584.
[16]
Alisi A, Pinzani M, Nobili V (2009) Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. Hepatology 50: 2048-2049. doi:10.1002/hep.23363. PubMed: 19937689.
[17]
Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443. doi:10.1016/S0016-5085(03)00907-7. PubMed: 12891546.
[18]
Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-J？rvinen H et al. (2010) From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42: 320-330. doi:10.1016/j.dld.2010.01.016. PubMed: 20207596.
[19]
Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L (2011) Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLOS ONE 6: e24363. doi:10.1371/journal.pone.0024363. PubMed: 21931690.
[20]
Hsiao TJ, Chen JC, Wang JD (2004) Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 28: 167-172. doi:10.1038/sj.ijo.0802519. PubMed: 14610526.
[21]
Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA et al. (2012) Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) 113: 1-6. doi:10.1152/japplphysiol.00127.2012. PubMed: 22582214.
[22]
Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM et al. (2013) Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology, 57: 1806–13. doi:10.1002/hep.26238. PubMed: 23325576.
[23]
Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33. doi:10.1002/hep.21223. PubMed: 16799979.
[24]
Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R et al. (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6: 1249-1254. doi:10.1016/j.cgh.2008.07.016. PubMed: 18995215.
[25]
Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078. doi:10.1002/hep.23050. PubMed: 19585618.
[26]
Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M et al. (2008) A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18: 1430-1437. doi:10.1007/s11695-008-9506-y. PubMed: 18500507.
[27]
Yilmaz Y (2009) Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 30: 1103-1109. doi:10.1111/j.1365-2036.2009.04148.x. PubMed: 19769633.
[28]
Fan JG (2010) Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 18: 163-166. PubMed: 20698076.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. doi:10.1002/hep.20701. PubMed: 15915461.
[31]
Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H et al. (2009) Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 17: 1696-1701. doi:10.1038/oby.2009.89.
[32]
Wong VW, Wong GL, Choi PC, Chan AW, Li MK et al. (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59: 969-974. doi:10.1136/gut.2009.205088. PubMed: 20581244.
[33]
Malik R, Chang M, Bhaskar K, Nasser I, Curry M et al. (2009) The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 24: 564-568. doi:10.1111/j.1440-1746.2008.05731.x. PubMed: 19378390.
[34]
Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M et al. (2013) Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 62: 392-399. doi:10.1016/j.metabol.2012.08.013. PubMed: 23036645.
[35]
Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55: 77-85. doi:10.1002/hep.24706. PubMed: 21953442.
[36]
Miele L, Forgione A, La Torre G, Vero V, Cefalo C et al. (2009) Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res 154: 194-201. doi:10.1016/j.trsl.2009.06.007. PubMed: 19766963.
[37]
Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A et al. (2010) Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 44: 440-447. PubMed: 20104187.
[38]
Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM et al. (2008) A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916-1923. doi:10.1002/hep.22241. PubMed: 18433022.
[39]
Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M et al. (2011) A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46: 257-268. doi:10.1007/s00535-010-0305-6. PubMed: 20842510.
[40]
Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M et al. (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33: 72-76. doi:10.1016/j.hepres.2005.09.007. PubMed: 16203174.
[41]
Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R et al. (2010) Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 51: 500-506. doi:10.1097/MPG.0b013e3181e376be. PubMed: 20808246.
[42]
Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ et al. (2010) A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32: 1315-1322. doi:10.1111/j.1365-2036.2010.04480.x. PubMed: 21050233.
[43]
Palekar NA, Naus R, Larson SP, Ward J, Harrison SA (2006) Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26: 151-156. doi:10.1111/j.1478-3231.2005.01209.x. PubMed: 16448452.
[44]
Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102: 399-408. doi:10.1111/j.1572-0241.2006.01041.x. PubMed: 17311652.
[45]
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M et al. (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 34. doi:10.1186/1471-230X-6-34. PubMed: 17096854.
[46]
Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E et al. (2012) Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol 10: 1162-1168. doi:10.1016/j.cgh.2012.06.019. PubMed: 22796457.
[47]
Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP et al. (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54: 1224-1229. doi:10.1016/j.jhep.2010.08.023. PubMed: 21145805.
[48]
Shen J, Chan HL, Wong GL, Choi PC, Chan AW et al. (2012) Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 56: 1363-1370. doi:10.1016/j.jhep.2011.12.025. PubMed: 22314419.
